The EGFR-T790M mutation associated with acquired resistance to first-generation EGFR tyrosine kinase inhibitors in Vietnamese Non-Small-Cell Lung Cancer patients
EGFR-T790M mutation with acquired resistance to first-generation EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Author affiliations
DOI:
https://doi.org/10.15625/2525-2518/18061Abstract
Background: non-small cell lung cancer (NSCLC) patients who had epidermal growth factor receptor (EGFR) mutations sensitive to EGFR tyrosine kinase inhibitors (TKIs) had a high response rate to target therapies. Epidermal growth factor receptor (EGFR) T790M mutation is the most common mechanism of acquired resistance to first-generation EGFR TKIs. Objective: The aim of this study was to analyze the incidence of EGFR T790 mutation, the progression-free survival (PFS) in the patients who progress on the first‑ generation EGFR‑TKIs. This study also investigates the correlation between T790M mutation and clinical, subclinical features, progression-free survival of NSCLC Vietnamese patients.
Patients and methods: We analyzed 66 NSCLC patients who had acquired resistance to first-generation EGFR-TKIs. The clinical data, PFS and the mechanism of acquired resistance were obtained. The Kaplan-Meier method and the log-rank test were used to analyze the PFS and compare between subgroups of patient characteristics. The correlations between the patient’s characteristics and EGFR-T790M mutation status were analyzed by Chi-square and Fisher’s exact tests.
Results: At the progressive period, EGFR T790M mutation was detected in 54.5% of patients. The median PFS were 14.48 ± 3.9 months (range: 8- 26 months). Patients who were older than 60 years old or had comorbidities had significantly shorter PFS than the subgroups without (P≤0.05). The age, gender, smoking status, comorbidities, pathological features were not significantly correlated with the development of EGFR-T790M (P > 0.05). The average PFS was not significantly different between the EGFR-T790M group and the non-EGFR-T790M group (P=0.642).
Conclusion: In our cohort study, more than half of all patients had T790M mutation after being treated with first-generation EGFR TKIs. Age and comorbidities were associated with PFS but the EGFR-T790M mutation was not correlated with PFS.
Downloads
Published
How to Cite
Issue
Section
License
![Creative Commons License](http://i.creativecommons.org/l/by-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vietnam Journal of Sciences and Technology (VJST) is an open access and peer-reviewed journal. All academic publications could be made free to read and downloaded for everyone. In addition, articles are published under term of the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA) Licence which permits use, distribution and reproduction in any medium, provided the original work is properly cited & ShareAlike terms followed.
Copyright on any research article published in VJST is retained by the respective author(s), without restrictions. Authors grant VAST Journals System a license to publish the article and identify itself as the original publisher. Upon author(s) by giving permission to VJST either via VJST journal portal or other channel to publish their research work in VJST agrees to all the terms and conditions of https://creativecommons.org/licenses/by-sa/4.0/ License and terms & condition set by VJST.
Authors have the responsibility of to secure all necessary copyright permissions for the use of 3rd-party materials in their manuscript.